Blistering disorders and their differential diagnosis and management

Size: px
Start display at page:

Download "Blistering disorders and their differential diagnosis and management"

Transcription

1 and their differential diagnosis and management STEVE KOSSARD, MB BS, PhD, FACD The type and pattern of cutaneous blisters may provide an essential clue to the diagnosis of specific dermatological disorders. Physical and chemical injury, insect bites, contact dermatitis, medications and infections are the most frequent causes of selflimited blisters in general practice. Individuals with persistent and puzzling forms of blistering disease may have a variety of autoimmune blistering skin disorders including bullous pemphigoid and pemphigus or have epidermolysis bullosa or porphyria. Drug-related blistering may mimic these dermatoses and should always be considered a potential cause. The development of blisters is a feature which is shared by a large number of skin disorders. The ultimate diagnosis often is readily apparent from the clinical history and presentation, but occasionally may require a range of investigations including skin biopsy, immunofluorescence or ultrastructural studies. Blisters are traditionally classified as vesicles if they measure less than 0,5 cm in diameter and bullae if they are larger. Superficially located blisters which are intraepidermal or subcorneal tend Dr Kossard is Consultant, Skin and Cancer Foundation, Darlinghurst; and Visiting Dermatologist, St Vincent's Hospital, Sydney, NSW, Australia. He wrote this article specially for MODERN MEDICINE. to be flaccid and transitory while subepidermal blisters are often tense and are more readily identified. A practical approach to the diagnosis of cutaneous vesiculobullous disorders is to consider common causes (Table 1) which may result in blisters prior to considering the bullous disorders as a special group. Common causes of skin blisters Chemical or physical injury This usually provides no difficulties in diagnosis and usually the blisters are painful, asymmetrical and correspond to the site of contact. Occasionally a chemical contactant may not be readily identified or suspected in the workplace. Contact dermatitis This is characterized by markedly pruritic vesiculobullous reactions which may have a Linear or streaked configuration (Figure 1) on the exposed sites due to plants such as the rhus tree (Figure 2). There is often a lag of 24 to 48 hours after contact with the allergen prior to the development of lesions, reflecting a delayed hypersensitivity reaction. Most cases can be managed with topical corticosteroids, but severe and extensive involvement may require a course of oral prednisone (Meticorten, et al) commencing at a dose of 40 mg in the morning, reducing by 10 mg weekly decrements for four weeks to avoid rebound of the rash. Insect bite reactions These often are scattered and appear as grouped excoriated pruritic papules on exposed TABLE 1 Common causes for skin blisters Physical or chemical injury Contact dermatitis Insect bites Herpes simplex Impetigo Drugs MODERN MEDICINE OF SOUTH AFRICA 9

2 continued Contact dermatitis may appear af t e r a [ a g 0f hours after contact with the allergen: this is a delayed hypersensitivity reaction. Figure 3. Grouped blisters on lower limbs due to insect Figure 4. Clusters of vesicles bites. cipated by sun exposure. sites. They are more often bullous in young children, migrants or the elderly (Figure 3). Insect bites may benefit symptomatically from the use of topical antihistamine creams; insect repellants should be utilized to diminish subsequent episodes. Herpes simplex Herpes simplex is readily recognized as grouped vesicles recurring at a localized site with MODERN MEDICINE OF SOUTH AFRICA 99

3 Impetigo blisters are superficial and continued I ten(i f0 transitory, resulting in multiple, crusted, highly contagious lesions. a self-limited course (Figure 4). Herpes may pose difficulties in diagnosis when the lesions are extensive in a primary episode or in disseminated infections and also when the lesions are at an unusual site. A Tzanck smear of the blister floor on a glass slide reveals viral giant cells allowing for rapid diagnosis. Acyclovir (Zovirax) has proved to be a valuable agent in the treatment of frequent recurrent episodes of herpes simplex and in disseminated infections, particularly in immunocompromised patients. Impetigo Impetigo blisters are superficially located and tend to be transitory resulting in multiple, crusted lesions which are highly contagious and usually are associated with staphylococcal infection. Blistering also may occur overlying a cellulitis due to Staphylococcus (Figure 5). Topical mupirocin ointment (Bactroban) is a useful addition for the treatment of localized impetigo. Drugs Drugs may cause blisters through a variety of mechanisms and may mimic a range of dermatoses which will be detailed prior to summarizing the varied drug reactions which may be bullous. Allergic and autoimmune bullous disorders (Table 2) Erythema multiforme Erythema multiforme represents an allergic reaction which is characterized by symmetrical papular eruption localized particularly to the extensor surfaces of the limbs. The lesions often have a target-like appearance and may be bull- Figure 5. Cellulitis with blisters due to staphylococcal Figure 7. Burn-like blisters infections. necrolysis. Figure 6. Target lesions associated with erythema multi- Figure 8. Tense blisters on forme. with bullous pemphigoid. 1 MODERN MEDICINE OF SOUTH AFRICA / OCTOBER 1990

4 continued. Dermatitis herpetiformis is intensely I p r u rm c ; although few patients have bowel symptoms, gluten-sensitive enteropathy is almost universal. Figure S. Linear deposition of immunoglobulin Figure 11. along Excoriated papulovesicular lesions i basement membrane zone seen on immunofluorescence metrical distribution on the trunk and elbows typica in bullous pemphigoid. matitis herpetiformis. Figure 10. Flaccid blisters on chest wall Figure of a patient 12. Blisters with and scars on the dorsum of ha pemphigus vulgaris. patient with porphyria. ous (Figure 6). Generalized erythema multiforme with severe involvement of the mucous membranes has been designated as the Stevens- Johnson syndrome. Extensive involvement of the skin may result in burn-like blisters termed "toxic epidermal necrolysis" (TEN) (Figure 7). Herpes simplex and drugs are the most frequent triggering MODERN MEDICINE OF SOUTH AFRICA 10

5 continued Pemphigus vulgaris used to be a fatal disorder, but the use of high dose oral steroids controls it: immunosuppressive agents have changed the outlook. factors for this reaction pattern. Acyclovir has been used prophylactically with success to prevent recurrent erythema multiforme triggered by herpes simplex. The use of oral corticosteroids has not been shown to alter the ultimate course of severe erythema multiforme. Bullous pemphigoid This may occur at all ages but particularly affects the elderly. It is characterized by urticarial plaques followed by tense blisters (Figure 8). Blisters are often generalized and may be accentuated in the flexural areas. A similar disorder termed "herpes gestationis" may occur during pregnancy. A variant of bullous pemphigoid involving the mucous membranes and resulting in scarring and occasionally blindness is termed "cicatricial pemphigoid". This group of autoimmune disorders all have circulating antibodies which are directed against the basement membrane zone (Figure 9) resulting in subepidermal blisters. Any elderly individual who suddenly develops widespread pruritic blisters which are tense should be biopsied as bullous pemphigoid can readily be diagnosed. Oral prednisone, commencing usually at a dose of 60 mg, remains the mainstay of management of bullous pemphigoid and usually needs to be continued for several years at a low dose (5-10 mg prednisone) to prevent relapse. Pemphigus vulgaris This is characterized by flaccid blisters often arising on normal skin (Figure 10). The peak incidence occurs in patients aged between 40 and 60 years. In most patients the initial lesions are localized to the oral mucous membranes. A superficial form which is localized particularly to the upper trunk and face may resemble impetigo and is termed "pemphigus foliaceus". Pemphigus is associated with circulating antibodies directed against the intercellular substance between the keratinocytes of the epidermis resulting in loss of intercellular adhesion and a process of acantholysis. Any chronic blistering or erosive process affecting the mucous membranes should be biopsied to rule out potentially serious bullous dermatoses such as pemphigus or cicatricial pemphigoid. Pemphigus vulgaris was formerly a fatal disorder but the use of high dose, oral steroids often exceeding 100 mg prednisone to bring the clinical activity under control and subsequent addition of immunosuppressive agents, such as azathioprine (Imuran, et al) has radically changed the outlook. Dermatitis herpetiformis This is an intensely pruritic disorder characterized by excoriated papulovesicular lesions localized particularly over the extensor surface of the elbows and knees and extending over the back (Figure 11), buttocks, face and scalp. The lesions may become bullous. The disorder occurs at all ages, but particularly in middle life. Skin biopsy 1 MODERN MEDICINE OF SOUTH AFRICA/OCTOBER 1990 shows neutrophilic microabscesses in the dermal papillae associated with granular IgA deposition demonstrable by immunofluorescence. Although the majority of patients do not have bowel symptoms, glutensensitive enteropathy is found almost universally. The control of this with a gluten-free diet has had a positive effect on the cutaneous disease. Dapsone, at a dosage of mg, remains the major form of treatment and often the rapidity of the clinical response is dramatic in dermatitis herpetiformis. Special bullous disorders Epidermolysis bullosa This is represented by a range of blistering disorders due to structural abnormalities in the skin affecting its capacity to resist injury. This group is characterized by mechanical fragility of the skin and ranges from fatal forms presenting in the neonatal period to mild forms confined to the palms and soles in adults. Ultrastructural studies have helped to separate subtypes and recently prenatal sampling has allowed early diagnosis to be established. The level of the blister in epidermolysis bullosa may occur intraepidermally (epidermolytic), through the basement membrane (junctional) or under the basement membrane (dermolytic). The dystrophic recessive form, which is dermolytic, leads to extensive scarring and may eventually be complicated by multiple skin cancers. Careful skin care and

6 1. SCHEDULING STATUS: S3 2. PROPRIETARY NAME (AND DOSAGE FORM): Lopid Capsules 3. COMPOSITION: Capsules containing 300mg gemfibrozil Special precautions: Diabetes Mellitus: As gemfibrozil may elevate the fasting blood sugarsduring treatment periodic blood sugar determinationsareadvisable in diabetics receiving LOPID toassureadequate control. Cholelithiasis: Because LOPID may increase cholesterol excretion into the bile leading to cholelithiasis, gallbladder studiesare indicated if cholelithiasis issuspected. LOPID therapy should be discontinued if gallstones are found. 4. PHARMACOLOGICAL CLASSIFICATION: Category A: 7.5 Serum-cholesterol reducers 5. PHARMACOLOGICAL ACTION: LOPID is a lipid-regulating agent which produces an increase in the cholesterol content of the high density lipoprotein (HDL) fraction and lowers elevated total serum cholesterol and triglycerideconcentrationsdue todecreases in thevery lowdensity lipoprotein (VLDL) and low density lipoprotein (LDL) fractions. The mechanism by which these actions occur has not been firmly established. In animalstudies LOPID has been shown to reduce the incorporation of long-chain fatty acids into rat liver triglycerides and to inhibit adipose tissue lipolysis. In humans LOPID inhibits peripheral lipolysis and decreasesthe hepatic uptake of plasma free fatty acids leading to reduced hepatic triglyceride production. It also inhibits the production and increases the turnover rate of the ^-apoprotein moiety of VLDL, the resulting decrease in VLDL providing the basis for the drug's ability to reduce total lipid levels. Lopid increases plasma HDL levels by stimulating the synthesis of the major apolipoproteins of HDL. 6. INDICATIONS: Lopid is indicated as adjunctive therapy to diet and weight loss in the treatment of the following hyperlipidaemias: 1. Fredrickson Type lla 2. Fredrickson Type lib 3. Fredrickson Type IV NOTE: LOPID should be prescribed only for patients with a potentially responsive lipid or lipoprotein abnormality where appropriate dietary therapy alone is insufficient to correct the condition. Excess body weight and excessive alcohol intake may be important factors in hypertriglyceridaemia and should be addressed prior to any drug therapy. Appropriate physical exercise may be a valuable ancillary measure. Contributory underlying pathology should be adequately treated e.g. hypothyroidism and diabetes mellitus. 7. CONTRA-INDICATIONS: (1) Hepatic and/or severe renal dysfunction, including primary biliary cirrhosis (2) Gall-stones (3) Hypersensitivity to gemfibrozil. Safe use in pregnancy has not yet been established. It is not known whether or not gemfibrozil is secreted in human milk. Gemfibrozil should be avoided during pregnancy and lactation. Safety and efficacy in children have not been established. 8. DOSAGE AND DIRECTIONS FOR USE: 1200mg in divided dosestwicedaily. 900mg in divided doses twice daily will prove sufficient in some patients and should be tried in cases of intolerance at normal dosage. When maximal triglyceride reduction is desired up to 1500mg daily in divided doses may be needed. 9. SIDE-EFFECTS AND SPECIAL PRECAUTIONS: Side-effects. The most frequently occurring side-effects are gastro-intestinal and include abdominal and epigastric pain, diarrhoea, dyspepsia and flatulence, nausea and vomiting. Other important side-effects include headache, fatigue, rash, dermatitis, pruritus, urticaria, vertigo, impotence, myositis manifesting as painful extremities and myalgia accompanied by an increase in creatine phosphokinase. Other possibly related side-effects to which the physician should be alerted include dry mouth, constipation, anorexia, blurred vision, paraesthesia and tinnitus, insomnia, malaiseand syncope, arthralgia, swollen jointsand musclecramps, back pain, hypokalemia, leucopenia and anaemia. Drug Interactions: As prothrombin time may be increased if coumarin-type anticoagulants are administered inconjunction with LOPID, caution should be exercised. The dosage of the anticoagulant should be reduced to maintain the prothrombin time at the desired level to prevent bleeding complications. Frequent prothrombin determinations are advisable until it has been definitely determined that the prothrombin level has stabilized. General Because long-term administration of LOPID may be needed, all baseline values including lipid profile, blood count and liver function tests, should be reliably measured beforetreatmentand periodicdeterminationsof serum lipidsshould be obtained. The drug should be withdrawn after 3 months if the response is inadequate. A paradoxical elevation of serum lipids has occasionally been observed, usually in patients with alcoholic hepatic disease. Mild haemoglobin, haematocrit and white blood celldecreases have been observed in occasional patients following initiation of LOPID therapy. However, these levels stabilize during long-term administration. Therefore, periodic blood counts are recommended during the first 12 months of LOPID administration. Abnormal liver function tests have been observed occasionally during LOPID administration, including elevationsofsgot.sgpt, LDH, and alkaline phosphatase. These are usually reversible when LOPID is discontinued. Therefore periodic liver function studies are recommended and LOPID therapy should be terminated if abnormalities persist. 10. KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT: Symptomatic and/or supportive treatment. 11. IDENTIFICATION: Capsule with white opaque body and maroon opaque cap, imprinted LOPID and LOPID 300 in grey ink. 12. PRESENTATION: 300mg capsules in packs of STORAGE INSTRUCTIONS: Store in a cool (15 C to 25 C), dry place out of the reach of children. 14. REGISTRATION NUMBER: S/7.5/295 Lopid reduces the risk by raising HDL and lowering LDL cholesterol 15. NAME AND BUSINESS ADDRESS OF THE APPLICANT: PARKE-DAVIS, Division of WARNER-LAMBERTS.A. (Pty) Ltd. 241 Main Road, RETREAT DATE OF PUBLICATION OF THIS PACKAGE INSERT: 7 February 1990

7 continued. Regular venesection to lower the serum iron levels has been the most important treatment of porphyria cutanea tarda. TABLE 2 Differential diagnosis of autoimmune bullous disorders Lesion Major sites Level of blister Immunofluorescence Bullous pemphigoid Tense blister Cicatricial pemphigoid Erosions, scars Herpes gestationis* Grouped blisters Pemphigus vulgaris Flaccid blister, erosions Pemphigus foliaceus Erosions, crusts Dermatitis herpetiformis Excoriated papulovesicles "During pregnancy and postpartum period Generalized skin Mucous membranes Trunk, limbs Mucous membrane Upper trunk, face Knees, elbows, buttocks (lamina lucida) (lamina lucida) (lamina lucida) Intraepidermal Subcorneal (under basal lamina) Linear; basement membrane zone Linear; basement membrane zone Linear; basement membrane zone Intercellular Intercellular Dermal papillae protection remains the mainstay of management in epidermolysis bullosa although occasionally phenytoin sodium (Epanutin) may benefit individual cases. Porphyria Porphyria presents characteristically in middle-aged individuals who have increased skin fragility and blisters over the dorsal aspect of their hands associated with scarring (Figure 12). Skin hyperpigmentation, hypertrichosis and facial suffusion may be additional signs. Oestrogens and alcohol may precipitate the disorder. Measurement of urinary porphyrins will establish the diagnosis. Regular venesection to lower the serum iron levels has been the most effective treat- TABLE 3 Bullous drug reactions Erythema muttiforme Fixed drug eaction Toxic epidermal necrolysis - Phototoxic Pseudoporphyria Pemphigus ment of porphyria cutanea tarda. Bullous drug reactions (Table 3) Erythema multiforme This may be precipitated by drugs such as sulphonamides, penicillin, phenytoin sodium and phenylbutazone. A fixed drug reaction This is characterized by localized erythematous plaques which may blister and typically heal with hyperpigmentation. The lesions may be on mucous surfaces, and recur at the same sites on readministration of the specific drug. Tetracyclines, sulphonamides and phenolphthalein are among the most common precipitants. Toxic epidermal necrolysis This is characterized by the sudden development of tender erythematous skin which is shed as loose sheets simulating a burn. It rapidly becomes generalized and is associated with mucous membrane involvement. Approximately 50% of patients follow a fatal course despite intensive treatment. Allopurinol, phenytoin sodium and sulphonamides are among the most common causes. Phototoxic drug reactions These mimic sunburn and may culminate with painful blisters on exposed sites. Thiazides, sulphonamides, tetracyclines and dithranol may result in phototoxic reactions. Pseudoporphyria This shows the same pattern of blistering as seen with porphyria, but urinary porphyrin studies give negative results. Nalidixic acid, tetracycline, frusemide and naproxen are the most frequently reported causes. Pemphigus This also may be precipitated by drugs and, in some cases, settle on discontinuing the medication. The most frequently reported drug associated with this is penicillamine, but other drugs including rifampicin and captopril may also induce this reaction. MODERN MEDICINE OF SOUTH AFRICA 10

B. Autoimmune blistering diseases

B. Autoimmune blistering diseases Go Back to the Top To Order, Visit the Purchasing Page for Details formation immediately above the basal layer. The dermal papillae, which are covered by basal cells in the single layer that is left in

More information

PROFESSIONAL INFORMATION

PROFESSIONAL INFORMATION SCHEDULING STATUS: S1 PROPRIETARY NAME AND DOSAGE FORM: Aleve Tablets COMPOSITION: Each tablet contains naproxen sodium 220 mg (equivalent to 200 mg naproxen) CATEGORY AND CLASS: A / 2.7 Antipyretic or

More information

Classification: 1. Infective: 2. Traumatic: 3. Idiopathic: Recurrent Aphthous Stomatitis (RAS) 4. Associated with systemic disease:

Classification: 1. Infective: 2. Traumatic: 3. Idiopathic: Recurrent Aphthous Stomatitis (RAS) 4. Associated with systemic disease: Classification: 1. Infective: 2. Traumatic: 3. Idiopathic: Recurrent Aphthous Stomatitis (RAS) 4. Associated with systemic disease: Hematological GIT Behcet s HIV 5. Associated with dermatological diseases:

More information

AROMASIN 25mg (Tablets)

AROMASIN 25mg (Tablets) APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate

More information

Emergency Dermatology Dr Melissa Barkham

Emergency Dermatology Dr Melissa Barkham Emergency Dermatology Dr Melissa Barkham Spotlight Seminar 30 th September 2010 Why is this important? Urgent recognition and treatment of dermatologic emergencies can be life saving and prevent long term

More information

CLINCOPATHOLOGICAL CASE

CLINCOPATHOLOGICAL CASE CLINCOPATHOLOGICAL CASE Generalized vesiculo-bullous and pustular eruption in an adult man Hassab El-Naby H, MD, El-Khalawany M, MD Department of Dermatology, Al-Azhar University, Cairo, Egypt CLINICAL

More information

Background information of DIF

Background information of DIF Napa Dermatopathology Meeting 2018: Immunobullous Disease Whitney A. High, MD, JD, MEng whitney.high@ucdenver.edu Professor of Dermatology & Pathology Vice-Chairman, Dermatology Director of Dermatopathology

More information

DERMATOLOGICAL EMERGENCIES. DR. Ian Hoyle MBBS DIP IMC RCS (Ed), DA (UK),FRACGP,FACRRM,DIP DERM(Wales) TASMANIAN SKIN AND BODY CENTRE

DERMATOLOGICAL EMERGENCIES. DR. Ian Hoyle MBBS DIP IMC RCS (Ed), DA (UK),FRACGP,FACRRM,DIP DERM(Wales) TASMANIAN SKIN AND BODY CENTRE DERMATOLOGICAL EMERGENCIES DR. Ian Hoyle MBBS DIP IMC RCS (Ed), DA (UK),FRACGP,FACRRM,DIP DERM(Wales) TASMANIAN SKIN AND BODY CENTRE Dermatological Emergencies INFECTIONS ERYTHRODERMA DRUG ERUPTIONS STEVENS-JOHNSON

More information

Paul K. Shitabata, M.D. Dermatopathology Institute

Paul K. Shitabata, M.D. Dermatopathology Institute Paul K. Shitabata, M.D. Dermatopathology Institute Technical Considerations Storage of slides at room temperature

More information

HEMORRHAGIC BULLOUS HENOCH- SCHONLEIN PURPURA: A CASE REPORT

HEMORRHAGIC BULLOUS HENOCH- SCHONLEIN PURPURA: A CASE REPORT HEMORRHAGIC BULLOUS HENOCH- SCHONLEIN PURPURA: A CASE REPORT Nirmala Ponnuthurai, Sabeera Begum, Lee Bang Rom Paediatric Dermatology Unit, Institute of Paediatric, Hospital Kuala Lumpur, Malaysia Abstract

More information

Dr Saleem Taibjee. Consultant Dermatologist & Dermatopathologist

Dr Saleem Taibjee. Consultant Dermatologist & Dermatopathologist Dr Saleem Taibjee saleem.taibjee@dchft.nhs.uk Consultant Dermatologist & Dermatopathologist Case S14-10797 and S15-4023 F50. Previous blistering, now marked milia on dorsum of hands. 4mm punch biopsy The

More information

Blistering skin conditions

Blistering skin conditions THEME weird skin stuff Belinda Welsh MBBS, MMed, FACD, is consultant dermatologist, St Vincent's Hospital, Melbourne and Sunbury Dermatology and Skin Cancer Clinic, Sunbury, Victoria. drbwelsh@bigpond.net.au

More information

THERE IS A GROUP OF PAtients. Defining Urticarial Dermatitis. A Subset of Dermal Hypersensitivity Reaction Pattern

THERE IS A GROUP OF PAtients. Defining Urticarial Dermatitis. A Subset of Dermal Hypersensitivity Reaction Pattern STUDY Defining Urticarial Dermatitis A Subset of Dermal Hypersensitivity Reaction Pattern Steven Kossard, FACD; Ian Hamann, FACD; Barbara Wilkinson, BSc Background: Urticarial dermatitis may represent

More information

A. Erythema multiforme and related diseases

A. Erythema multiforme and related diseases Go Back to the Top To Order, Visit the Purchasing Page for Details Chapter Erythema, Erythroderma (Exfoliative Dermatitis) Erythema is caused by telangiectasia or hyperemia in the papillary and reticular

More information

Egyptian Dermatology Online Journal Vol. 8 No 2: 6, December Yasmeen J Bhat*, Iffat Hasan*, Atiya Yaseen*, Hina Altaf*, Shylla Mir**

Egyptian Dermatology Online Journal Vol. 8 No 2: 6, December Yasmeen J Bhat*, Iffat Hasan*, Atiya Yaseen*, Hina Altaf*, Shylla Mir** Pemphigoid gestationis in a multigravida Yasmeen J Bhat*, Iffat Hasan*, Atiya Yaseen*, Hina Altaf*, Shylla Mir** * Department of Dermatology, STD & Leprosy; Government Medical College, Srinagar ** Department

More information

السكري للداء مرافقة فقاعات diabeticorum= Bullosis

السكري للداء مرافقة فقاعات diabeticorum= Bullosis 1 / 6 Bullosis diabeticorum Bullous disease of diabetes (bullosis diabeticorum) is a distinct, spontaneous, noninflammatory, blistering condition of acral skin unique to patients with diabetes mellitus.

More information

A case of bullous pemphigoid following pemphigus foliaceus

A case of bullous pemphigoid following pemphigus foliaceus #2228 A case of bullous pemphigoid following pemphigus foliaceus Priyanka Vedak MD 1, Danielle Levine MD 1,3, Lyn Duncan MD 2,3, Hensin Tsao 1,3, Daniela Kroshinsky MD MPH 1,3 1. Department of Dermatology,

More information

Rosuvastatin 5 mg, 10 mg and 20 mg Tablet

Rosuvastatin 5 mg, 10 mg and 20 mg Tablet Rosuvastatin 5 mg, 10 mg and 20 mg Tablet Description is a preparation of Rosuvastatin. Rosuvastatin is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to

More information

* Adults. NSAID associated peptic ulceration: - Acute treatment: 150 mg twice daily for 8 to 12 weeks, or 300mg nocte.

* Adults. NSAID associated peptic ulceration: - Acute treatment: 150 mg twice daily for 8 to 12 weeks, or 300mg nocte. Trade Name Aciloc 75 mg & 300 mg Film-coated tablets Generic Name Ranitidine Composition Each Aciloc 300 mg film-coated tablet contains: - Active ingredient: Ranitidine hydrochloride 336 mg equivalent

More information

TILAZEM. Diltiazem hydrochloride 240 mg

TILAZEM. Diltiazem hydrochloride 240 mg Tilazem Capsules Page 1 of 9 TILAZEM Diltiazem hydrochloride SCHEDULING STATUS: S3 PROPRIETARY NAME (AND DOSAGE FORM): TILAZEM 180 CR (controlled-release capsule) TILAZEM 240 CR (controlled-release capsule)

More information

Pharmacologyonline 1: 1-6 (2010) Case Report Ravishankar and Hiremath CIPROFLOXACIN INDUCED BULLOUS PEMPHIGOID: A CASE REPORT

Pharmacologyonline 1: 1-6 (2010) Case Report Ravishankar and Hiremath CIPROFLOXACIN INDUCED BULLOUS PEMPHIGOID: A CASE REPORT CIPROFLOXACIN INDUCED BULLOUS PEMPHIGOID: A CASE REPORT Ravishankar AC 1*, Hiremath SV 1 1 Dept of Pharmacology and Pharmacotherapeutics, JN Medical College, Belgaum, India. Summary Bullous pemphigoid

More information

An Approach to Common and not so Common Rashes in the Office FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc

An Approach to Common and not so Common Rashes in the Office FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc An Approach to Common and not so Common Rashes in the Office FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc 1 Common Rashes Tinea Corporis: Annular- this is not the only criteria Advancing erythematous

More information

EMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated

EMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated EMILOK Global (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated granules. Properties: Emilok (omeprazole) belongs to the group of proton pump inhibitors, inhibits both

More information

SCHEDULING STATUS: S0 For pack sizes of 24 tablets or less. For pack sizes of more than 24 tablets

SCHEDULING STATUS: S0 For pack sizes of 24 tablets or less. For pack sizes of more than 24 tablets SCHEDULING STATUS: S0 For pack sizes of 24 tablets or less S1 For pack sizes of more than 24 tablets PROPRIETARY NAME: AND DOSAGE FORM PANADO MELTABS (Tablets) COMPOSITION: Each tablet contains 500 mg

More information

Autoimmune Diseases with Oral Manifestations

Autoimmune Diseases with Oral Manifestations Autoimmune Diseases with Oral Manifestations Martin S. Greenberg DDS, FDS RCSEd Professor Emeritus Department of Oral Medicine University of Pennsylvania Disclosure Statement I have no actual or potential

More information

Metformin Hydrochloride

Metformin Hydrochloride Metformin Hydrochloride 500 mg, 850 mg, 500 mg LA and 750 mg LA Tablet Description Informet is a preparation of metformin hydrochloride that belongs to a biguanide class of oral antidiabetic drugs. Metformin

More information

50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate).

50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate). DUPISOR Composition Gel 50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate). Action Calcipotriol is a non-steroidal antipsoriatic agent, derived from vitamin D. Calcipotriol

More information

Cetirizine Proposed Core Safety Profile

Cetirizine Proposed Core Safety Profile Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Lopid 450 mg film-coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 450 mg gemfibrozil. For

More information

0BCore Safety Profile. Pharmaceutical form(s)/strength: Cream 1% DK/H/PSUR/0009/005 Date of FAR:

0BCore Safety Profile. Pharmaceutical form(s)/strength: Cream 1% DK/H/PSUR/0009/005 Date of FAR: 0BCore Safety Profile Active substance: Pimecrolimus Pharmaceutical form(s)/strength: Cream 1% P-RMS: DK/H/PSUR/0009/005 Date of FAR: 06.06.2013 4.3 Contraindications Hypersensitivity to pimecrolimus,

More information

COPYRIGHTED MATERIAL. Introduction CHAPTER 1. Introduction

COPYRIGHTED MATERIAL. Introduction CHAPTER 1. Introduction CHAPTER 1 Introduction OVERVIEW The clinical features of skin lesions are related to the underlying pathological processes. Broadly skin conditions fall into three clinical groups: (a) those with a well-defined

More information

Cutaneous Drug Reactions

Cutaneous Drug Reactions Cutaneous Drug Reactions Andrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada Copyright 2017 by Sea Courses

More information

Children Enteric coated tablet : 1-3 mg/kg per day in divided doses.

Children Enteric coated tablet : 1-3 mg/kg per day in divided doses. Ultrafen Tablet/SR Tablet/Suppository/Gel Description Ultrafen is a preparation of Diclofenac is a non-steroidal antiinflammatory agent with marked analgesic, anti-inflammatory and antipyretic properties.

More information

Figure 25.1 Figure 25.2

Figure 25.1 Figure 25.2 CASE 25 Patient: A 75-year-old Thai man from Lamphun Chief Complaint: 6-month-history of itchy vesicles at both thighs and elbows, upper back and sacral area Present Illness: The patient presented with

More information

Acquired and Inherited Bullous Diseases

Acquired and Inherited Bullous Diseases Acquired and Inherited Bullous Diseases Erin Wei MD Brigham and Women s Hospital, Department of Dermatology Instructor, Harvard Medical School Director, Bullous Disease Clinic No disclosures Conflict of

More information

Action Naproxen sodium, the active principle of Naproxan, has been developed as an analgesic because it is more rapidly absorbed than Naproxen.

Action Naproxen sodium, the active principle of Naproxan, has been developed as an analgesic because it is more rapidly absorbed than Naproxen. NAPROXAN Composition Each tablet contains Naproxen sodium 275 mg. Tablets Action Naproxen sodium, the active principle of Naproxan, has been developed as an analgesic because it is more rapidly absorbed

More information

Meningococcal polysaccharide vaccine Group A, Group C, Group Y and Group W-135

Meningococcal polysaccharide vaccine Group A, Group C, Group Y and Group W-135 MENOMUNE ACYW-135 Meningococcal polysaccharide vaccine Group A, Group C, Group Y and Group W-135 Description The vaccine is a freeze-dried preparation of the group specific antigens from Neisseria meningitidis,

More information

Immodium / loprarmide

Immodium / loprarmide Immodium / loprarmide IMODIUM (loperamide hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease.

More information

Vulval dermatoses. Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough

Vulval dermatoses. Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough Vulval dermatoses Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough Pigmentation Vulvodynia Ulcers Genetic Pruritus VULVAL

More information

VARICELLA. Infectious and Tropical Pediatric Division, Department of Child Health, Medical Faculty, University of Sumatera Utara

VARICELLA. Infectious and Tropical Pediatric Division, Department of Child Health, Medical Faculty, University of Sumatera Utara VARICELLA (Chicken pox) Infectious and Tropical Pediatric Division, Department of Child Health, Medical Faculty, University of Sumatera Utara Definition : Varicella is a common contagious disease caused

More information

Emergency Dermatology. Emergency Dermatology

Emergency Dermatology. Emergency Dermatology Emergency Dermatology These are rapidly progressive skin conditions and some are potentially lifethreatening. Early recognition is important to implement prompt supportive care and therapy. Some are drug

More information

What s causing this rash?

What s causing this rash? Case 1 What s causing this rash? A 38-year-old woman presents with a pruritic, tender rash on the trunk and extremities that has not changed over the past few days (Figure 1). She has taken fluvastatin

More information

Vesiculobullous Diseases

Vesiculobullous Diseases Vesiculobullous Diseases Larkin Community Hospital/NSU-COM Presenters: Yuri Kim, DO, Sam Ecker, DO, Jennifer David, DO, MBA Program Director: Stanley Skopit, DO, MSE, FAOCD, FAAD We have no relevant disclosures

More information

Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml SI/H/PSUR/0002/002 Date of FAR:

Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml SI/H/PSUR/0002/002 Date of FAR: 0BCore Safety Profile Active substance: Ceftibuten Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml P-RMS: SI/H/PSUR/0002/002 Date of FAR: 14.02.2013

More information

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials. Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs

More information

atorvastatin 10mg, amlodipine 5mg and dilitazem 60mg. He had unexplained iron deficiency anaemia (hemoglobin-8.4gm/dl, ferritin- 4.73ng/ml, total iron

atorvastatin 10mg, amlodipine 5mg and dilitazem 60mg. He had unexplained iron deficiency anaemia (hemoglobin-8.4gm/dl, ferritin- 4.73ng/ml, total iron Pemphigus herpetiformis : A rare clinical variant of pemphigus Shrestha P 1, Tajhya RB 2, Pokharel A 3 1,2 Consultant Dermatologist, Department of Dermatology, Vayodha Hospital Pvt. Ltd, Balkhu, Kathmandu,

More information

DERMATOLOGY SKIN DISEASE: APPROACH TO DIAGNOSIS

DERMATOLOGY SKIN DISEASE: APPROACH TO DIAGNOSIS DERMATOLOGY SKIN DISEASE: APPROACH TO DIAGNOSIS History Clinical Examination List and Prioritise Differentials Diagnostic Testing/Trials (eg Treatment Trial) Correlate All Findings History Signalment age,

More information

Proceedings of the Southern European Veterinary Conference - SEVC -

Proceedings of the Southern European Veterinary Conference - SEVC - Close this window to return to IVIS www.ivis.org Proceedings of the Southern European Veterinary Conference - SEVC - Sep. 30-Oct. 3, 2010, Barcelona, Spain Next SEVC Conference: Sep. 30-Oct. 2, 2011 -

More information

TERRY WHITE CHEMISTS GEMFIBROZIL TABLETS

TERRY WHITE CHEMISTS GEMFIBROZIL TABLETS TERRY WHITE CHEMISTS GEMFIBROZIL TABLETS NAME OF THE MEDICINE Gemfibrozil. Chemical name: 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid. Structural Formula Me Me Me O COOH Me Molecular Formula: C

More information

Prescribing Information

Prescribing Information Prescribing Information Pr DERMOVATE Cream (clobetasol propionate cream, USP) Pr DERMOVATE Ointment (clobetasol propionate ointment, USP) Topical corticosteroid TaroPharma Preparation Date: A Division

More information

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet

More information

INDICATIONS ACULAR 0,4% ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.

INDICATIONS ACULAR 0,4% ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. Page 1 SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) ACULAR 0,4% COMPOSITION ACULAR 0,4% ophthalmic solution contains: Ketorolac tromethamine: 4 mg/ml Preservative: Benzalkonium chloride

More information

Antihyperlipidemic Drugs

Antihyperlipidemic Drugs Antihyperlipidemic Drugs Lipid disorders: Disorders of lipid metabolism are manifest by elevation of the plasma concentrations of the various lipid and lipoprotein fractions (total and LDL cholesterol,

More information

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults

More information

Cutaneous Adverse Drug Reactions in Domestic Animals. Katherine Doerr, DVM, Dip. ACVD. Veterinary Dermatology Center

Cutaneous Adverse Drug Reactions in Domestic Animals. Katherine Doerr, DVM, Dip. ACVD. Veterinary Dermatology Center Cutaneous Adverse Drug Reactions in Domestic Animals Katherine Doerr, DVM, Dip. ACVD Veterinary Dermatology Center Maitland, Rockledge, Waterford Lakes, FL Not highly studied in veterinary medicine Unknown

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate

More information

Clinical diagnosis? AIP (Acute Intermittent Porphyria)

Clinical diagnosis? AIP (Acute Intermittent Porphyria) Case 1 18 yo woman came to ER with a 5-day history of severe abdominal pain Localized, intermittent, sharp, epigastric and periumbilical pain associated with mild nausea but no vomiting for the past 6

More information

Etoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets , Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN

Etoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets , Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN Etoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets 23.5.2016, Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary Etoricoxib STADA 30 mg film-coated

More information

Epidermolysis Bullosa Acquisita

Epidermolysis Bullosa Acquisita Introduction Epidermolysis Bullosa Acquisita Pages with reference to book, From 192 To 194 Nasser Rashid Dar ( Departments of Dermatology, Combined Military Hospital, Peshawar. ) Ahsan Hameed, Ashfaq Ahmad

More information

If a drug trigger is suspected, stop the offending drug as this may reduce the risk of relapse.

If a drug trigger is suspected, stop the offending drug as this may reduce the risk of relapse. There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've

More information

VANLID Capsules (Vancomycin hydrochloride)

VANLID Capsules (Vancomycin hydrochloride) Published on: 22 Sep 2014 VANLID Capsules (Vancomycin hydrochloride) Composition VANLID Capsules Each capsule contains: Vancomycin Hydrochloride IP equivalent to Vancomycin.. 250 mg Approved colours used

More information

Department of Dermatology, Christian Medical College and Hospital, Ludhiana, Punjab, India.

Department of Dermatology, Christian Medical College and Hospital, Ludhiana, Punjab, India. Bullous pemphigoid mimicking granulomatous inflammation Abhilasha Williams, Emy Abi Thomas. Department of Dermatology, Christian Medical College and Hospital, Ludhiana, Punjab, India. Egyptian Dermatology

More information

Nicotinic Acid Nicotinic Acid

Nicotinic Acid Nicotinic Acid Nicotinic Acid Nicotinic Acid PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Nicotinic acid BP 250 mg. Structural formula: Molecular weight: 123.1 CAS Registry no.: 59-67-6 DESCRIPTION Inactive

More information

Future of Pediatrics: Blisters, Hives and Other Tales from the Emergency Room June 14 th, 2016

Future of Pediatrics: Blisters, Hives and Other Tales from the Emergency Room June 14 th, 2016 A. Yasmine Kirkorian MD Assistant Professor of Dermatology & Pediatrics Children s National Health System George Washington University School of Medicine & Health Sciences Future of Pediatrics: Blisters,

More information

Original Contribution

Original Contribution Direct Immunofluorescence Test of Skin Biopsy Samples Results of 204 Cases Kabir AN, 1 Das RK, 2 Kamal M 3 Direct immunofluorescence (DIF) test of skin and renal biopsy specimens is being done on regular

More information

Rashes Not To Be Missed In Children

Rashes Not To Be Missed In Children May 2016 Rashes Not To Be Missed In Children Dr Chan Yuin Chew Dermatologist Dermatology Associates Gleneagles Medical Centre Scope of presentation Focus on rashes May lead to significant morbidity if

More information

Dermatitis Herpetiformis (DH) in Association with H. pylori Infection: Description of a Case Report

Dermatitis Herpetiformis (DH) in Association with H. pylori Infection: Description of a Case Report British Journal of Medicine & Medical Research 1(3): 163-169, 2011 SCIENCEDOMAIN international www.sciencedomain.org Dermatitis Herpetiformis (DH) in Association with H. pylori Infection: Description of

More information

To Correlate Clinical Diagnosis with Histopathology and DIF Pattern of Autoimmune Based Vesiculobullous Disorders In A Tertiary Teaching Hospital

To Correlate Clinical Diagnosis with Histopathology and DIF Pattern of Autoimmune Based Vesiculobullous Disorders In A Tertiary Teaching Hospital IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 7 Ver. 2 (July. 2018), PP 01-06 www.iosrjournals.org To Correlate Clinical Diagnosis with Histopathology

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 100 mg of trimethoprim. For the full list of excipients, see section 6.1.

SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 100 mg of trimethoprim. For the full list of excipients, see section 6.1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Trimethoprim 100 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 100 mg of trimethoprim. For the full list

More information

APPROVED PACKAGE INSERT

APPROVED PACKAGE INSERT Page 1 of 6 APPROVED PACKAGE INSERT SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: CYKLOKAPRON T 500 (Tablets) CYKLOKAPRON IV 500 (Injection) COMPOSITION: Each tablet contains 500 mg tranexamic

More information

Pfizer Laboratories (Pty) Ltd P&U Etoposide CSV Range Approved PI: 12 Sep 2005 Page 1 of 5

Pfizer Laboratories (Pty) Ltd P&U Etoposide CSV Range Approved PI: 12 Sep 2005 Page 1 of 5 Approved PI: 12 Sep 2005 Page 1 of 5 SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): P&U ETOPOSIDE CSV 100 mg/5 ml INJECTION (INJECTION CONCENTRATE FOR INTRAVENOUS INFUSION) P&U ETOPOSIDE CSV

More information

PACKAGE INSERT. 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole sodium, equivalent

PACKAGE INSERT. 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole sodium, equivalent PACKAGE INSERT SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) PARIET 10 mg tablets PARIET 20 mg tablets COMPOSITION 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole

More information

Clinicopathological correlation of blistering diseases of skin

Clinicopathological correlation of blistering diseases of skin Bangladesh Med Res Counc Bull 2008; 34: 48-53 Copyright 2008 by Bangladesh Medical Research Council Clinicopathological correlation of blistering diseases of skin A.K.M. Nurul Kabir 1, Mohammed Kamal 1

More information

GROUP 15 TOPICAL PREPARATIONS

GROUP 15 TOPICAL PREPARATIONS - 105 - GROUP 15 15.1 DERMATOLOGICAL PREPARATIONS 15.1.1 TOPICAL ANTIFUNGALS CLOTRIMAZOLE Indication: Treatment of susceptible fungal infections, dermatophytoses, superficial mycoses, and cutaneous candidiasis

More information

APPROVED PACKAGE INSERT

APPROVED PACKAGE INSERT APPROVED PACKAGE INSERT SCHEDULING STATUS:S3 PROPRIETARY NAMES (AND DOSAGE FORMS): PONSTAN (CAPSULES) PONSTAN FORTE (TABLET) PONSTAN (SUSPENSION) PONSTAN (PAEDIATRIC SUPPOSITORIES) COMPOSITION: PONSTAN

More information

INDICATIONS ACULAR 0,5 % is indicated for the relief of inflammation following ocular surgery.

INDICATIONS ACULAR 0,5 % is indicated for the relief of inflammation following ocular surgery. Page 1 of 5 SCHEDULING STATUS Schedule 3 PROPRIETARY NAME (AND DOSAGE FORM) ACULAR 0,5 % COMPOSITION ACULAR 0,5 % contains: Preservatives: Benzalkonium chloride 0,01 % m/v Disodium edetate 0,1 % m/v PHARMACOLOGICAL

More information

Dialosa 1 mg, 2 mg, 3 mg, 4 mg and 6 mg tablets Glimepiride

Dialosa 1 mg, 2 mg, 3 mg, 4 mg and 6 mg tablets Glimepiride PACKAGE LEAFLET: INFORMATION FOR THE USER Dialosa 1 mg, 2 mg, 3 mg, 4 mg and 6 mg tablets Glimepiride Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You may

More information

2018 Oregon Dental Conference Course Handout Denis Lynch, DDS, PhD

2018 Oregon Dental Conference Course Handout Denis Lynch, DDS, PhD 2018 Oregon Dental Conference Course Handout Denis Lynch, DDS, PhD Course 9148: Diagnosis and Treatment of Recurrent Oral Ulcers Friday, April 6 9 am - 12 pm Diagnosis and Treatment of Recurrent Oral Ulcers

More information

ANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD

ANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed

More information

CHOLESTAGEL 625 mg Genzyme

CHOLESTAGEL 625 mg Genzyme CHOLESTAGEL 625 mg Genzyme 1. NAME OF THE MEDICINAL PRODUCT Cholestagel 625 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 625 mg colesevelam hydrochloride (hereafter

More information

AUSTRALIAN PRODUCT INFORMATION APOC-5FU CREAM (FLUOROURACIL)

AUSTRALIAN PRODUCT INFORMATION APOC-5FU CREAM (FLUOROURACIL) AUSTRALIAN PRODUCT INFORMATION APOC-5FU CREAM (FLUOROURACIL) 1 NAME OF THE MEDICINE Fluorouracil 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM APOC-5FU cream is intended for

More information

Pemphigus in younger age group in Bangladeshi population

Pemphigus in younger age group in Bangladeshi population ORIGINAL ARTICLE in younger age group in Bangladeshi population Abdul Wahab 1, MD, Lubna Khondker 1, MD, Jamal Uddin 1, MD, Ishrat Bhuiyan 2, MD Shirajul Islam Khan 3, MD, Zafrul Islam 1, MD, Rahmat Ali

More information

A cross-sectional study of clinical, histopathological and direct immmunofluorescence diagnosis in autoimmune bullous diseases

A cross-sectional study of clinical, histopathological and direct immmunofluorescence diagnosis in autoimmune bullous diseases Original Article A cross-sectional study of clinical, histopathological and direct immmunofluorescence diagnosis in autoimmune bullous diseases Anchal Jindal, MD 1 Rushikesh Shah, MBBS 2 Neela Patel, MD

More information

CASE REPORT ATYPICAL BULLOUS PYODERMA GANGRENOSUM WITH EARLY LESIONS MIMICKING CHICKEN POX

CASE REPORT ATYPICAL BULLOUS PYODERMA GANGRENOSUM WITH EARLY LESIONS MIMICKING CHICKEN POX ATYPICAL BULLOUS PYODERMA GANGRENOSUM WITH EARLY LESIONS MIMICKING CHICKEN POX Ramesh M 1, Kavya Raju Nayak 2, M.G. Gopal 3, Sharath Kumar B.C 4, Nandini A.S 5 HOW TO CITE THIS ARTICLE: Ramesh M, Kavya

More information

Pediatric Dermatology

Pediatric Dermatology Pediatric Dermatology --------- Emergencies & Urgencies Nicholas V. Nguyen, M.D. Director, Pediatric Dermatology Disclosures In the past 12 months, I have had the following financial relationships with

More information

of LDL and HDL cholesterol.

of LDL and HDL cholesterol. Ezetimibe Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about. It does not contain all the available information. It does not take the place of talking

More information

Package leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride

Package leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride Package leaflet: Information for the patient / / 30 mg/5 ml syrup Ambroxol hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Questions. Answers. Share your photos and diagnoses with us!

Questions. Answers. Share your photos and diagnoses with us! Illustrated quizzes on problems seen in everyday practice Case 1 A 56-year-old woman presented with a two-week history of pruritic urticarial plaques and tense bullae on both erythematous and normal skin.

More information

M0BCore Safety Profile

M0BCore Safety Profile M0BCore Safety Profile Active substance: Aztreonam Pharmaceutical form(s)/strength: 500 mg, 1 g and 2 g powder for solution for injection and infusion NB! 75mg aztreonam for nebulisation to treat infections

More information

PAEDIATRIC ACUTE CARE GUIDELINE. Impetigo. This document should be read in conjunction with this DISCLAIMER

PAEDIATRIC ACUTE CARE GUIDELINE. Impetigo. This document should be read in conjunction with this DISCLAIMER Princess Margaret Hospital for Children PAEDIATRIC ACUTE CARE GUIDELINE Impetigo Scope (Staff): Scope (Area): All Emergency Department Clinicians Emergency Department This document should be read in conjunction

More information

Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults

Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults First Lower Dose NSAID Using SoluMatrix Fine Particle Technology to be Reviewed

More information

Prescribing Information. Taro-Clobetasol. Taro-Clobetasol

Prescribing Information. Taro-Clobetasol. Taro-Clobetasol Prescribing Information Pr Taro-Clobetasol Clobetasol Propionate Cream USP, 0.05% w/w Pr Taro-Clobetasol Clobetasol Propionate Ointment USP, 0.05% w/w Therapeutic Classification Topical corticosteroid

More information

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR: 0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 13.06.2013 4.2 Posology and method of administration

More information

Some skin conditions

Some skin conditions Some skin conditions Some skin conditions Acute Inflammatory Dermatoses Chronic Inflammatory Dermatoses Blistering (Bullous) Diseases Panniculitis Disorders of Epidermal Appendages -Urticaria -Acute eczematous

More information

Ausfam PRODUCT INFORMATION NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY

Ausfam PRODUCT INFORMATION NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY Ausfam PRODUCT INFORMATION NAME OF THE MEDICINE Famotidine. The chemical name for famotidine is N 2 -(aminosulphonyl)-3-[[[2-[(diamino methylene)amino]thiazol-4yl]methyl]thio]propanamidine. Its structural

More information

CUTANEOUS DRUG REACTIONS OR I WOULDN T HAVE SEEN IT, IF I HADN T BELIEVED IT Edmund J. Rosser Jr., DVM, DACVD

CUTANEOUS DRUG REACTIONS OR I WOULDN T HAVE SEEN IT, IF I HADN T BELIEVED IT Edmund J. Rosser Jr., DVM, DACVD CUTANEOUS DRUG REACTIONS OR I WOULDN T HAVE SEEN IT, IF I HADN T BELIEVED IT Edmund J. Rosser Jr., DVM, DACVD DERMATOLOGY Pathogenesis Immunologic: can involve Type I, II, III, IV hypersensitivity reactions.

More information

Important Safety Information

Important Safety Information THALOMID (thalidomide) in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM) THALOMID is indicated for the acute treatment of the cutaneous

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Colecalciferol Meda 800 IU tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains colecalciferol (vitamin D 3 ) 800 IU

More information

PIL. ParaCet Flu 500 mg+250 mg/sachet Powder for oral solution paracetamol + ascorbic acid

PIL. ParaCet Flu 500 mg+250 mg/sachet Powder for oral solution paracetamol + ascorbic acid PIL ParaCet Flu 500 mg+250 mg/sachet Powder for oral solution paracetamol + ascorbic acid Please, carefully read this PIL before you start using the medicine. This medicine is available without prescription,

More information

EULEXIN PRODUCT INFORMATION NAME OF MEDICINE EULEXIN DESCRIPTION

EULEXIN PRODUCT INFORMATION NAME OF MEDICINE EULEXIN DESCRIPTION EULEXIN PRODUCT INFORMATION NAME OF MEDICINE EULEXIN DESCRIPTION Each EULEXIN tablet contains 250 mg of flutamide, a non-steroidal, orally active antiandrogen. Each tablet also contains lactose anhydrous,

More information